Valuation : HLS Therapeutics Inc.

Market Cap 80.69M 69.61M 65.57M 59.75M 112M 7.62B 113M 776M 301M 3.9B 303M 296M 12.8B P/E 2026 *
-12.6x
P/E 2027 * -37.3x
Enterprise Value 80.69M 69.61M 65.57M 59.75M 112M 7.62B 113M 776M 301M 3.9B 303M 296M 12.8B EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.24x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day-3.73%
1 week-1.10%
Current month-3.73%
1 month-14.05%
3 months-18.69%
6 months-19.60%
Current year-25.10%
1 week 3.61
Extreme 3.61
3.88
1 month 3.56
Extreme 3.56
4.29
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Buy

Chief Executive Officer

500 0.0016%
17/8/26 Buy

Chief Executive Officer

2,000 0.0064%
31/7/26 TaxCompany 1,000 0.0032% -
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%-1.10%-33.15%-22.70% 80.69M
+1.99%+3.14%+33.71%+124.28% 108B
+2.57%+2.97%+64.15%+180.30% 57.1B
+0.00%+2.67%-12.94%+240.51% 22.36B
-0.24%-0.43%-12.10%-8.35% 8.12B
-0.91%-0.66%-39.47%-28.89% 7.08B
+0.45%+6.02%+10.67%+26.15% 6.78B
+0.78%-2.21%-16.25%-32.78% 6.1B
-0.03%-0.60%-4.25%+20.61% 5.12B
+0.58%+7.33%+307.68%+476.70% 4.45B
Average +0.15%+1.42%+29.81%+97.58% 22.5B
Weighted average by Cap. +1.61%+1.53%+35.32%+137.77%

Financials

2026 *2027 *
Net sales 58.44M 50.41M 47.49M 43.27M 80.88M 5.52B 81.49M 562M 218M 2.82B 219M 215M 9.27B 65.03M 56.1M 52.84M 48.15M 90M 6.14B 90.67M 626M 243M 3.14B 244M 239M 10.32B
Net income -5.47M -4.72M -4.44M -4.05M -7.57M -517M -7.63M -52.62M -20.42M -264M -20.54M -20.09M -868M -2.16M -1.87M -1.76M -1.6M -3M -204M -3.02M -20.83M -8.08M -105M -8.13M -7.95M -343M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
02/09/26 CAD 3.610 -3.73% 8,800
01/09/26 CAD 3.750 0.00% 17,400
31/08/26 CAD 3.750 -1.06% 29,107
28/08/26 CAD 3.790 +2.43% 52,047
27/08/26 CAD 3.700 +1.37% 34,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.608USD
Average target price
5.286USD
Spread / Average Target
+102.66%

Quarterly revenue - Rate of surprise